

Edgar Filing: HEMISPHERX BIOPHARMA INC - Form 10-Q/A

HEMISPHERX BIOPHARMA INC
Form 10-Q/A
August 20, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q/A-2

Quarterly Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

For the Quarterly Period Ended September 30, 2002

Commission File Number: 0-27072

HEMISPHERx BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

Delaware

52-0845822

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

1617 JFK Boulevard, Suite 660, Philadelphia, PA 19103

(Address of principal executive offices) (Zip Code)

(215) 988-0080

(Registrant's telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since
last report)

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.

/X/ Yes / / No

32,080,270 shares of common stock issued and outstanding as of October
31, 2002.

Explanatory Note:

This amendment to our quarterly report on Form 10-Q only amends Part II,
item 4, which information was inadvertently not included in the original
filing.

Part II OTHER INFORMATION

ITEM 4: Submission of Matters to a Vote of Security Holders

At the Companys Annual Meeting of Stockholders on August 14, 2002,
stockholders approved the following:

Edgar Filing: HEMISPHERX BIOPHARMA INC - Form 10-Q/A

1. Election of the following five members to the Board of Directors of Hemispherx to serve until their respective successors are elected and qualified:

	For -----	Authority Withheld -----
William A. Carter	16,731,321	6,518,542
Richar C. Piani	22,487,863	762,000
Ransom W. Etheridge	15,958,340	7,291,523
William M. Mitchell	22,489,663	760,200
Iraj-Eqhbali Kiani	21,873,467	1,376,396

2. Ratification the selection by Hemispherx of BDO Seidman LLP, independent public accountants, to audit the financial statements of Hemispherx for the year ending December 31, 2003.

For -----	Against -----	Abstain -----
21,872,283	1,355,200	22,380

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

HEMISPHERx BIOPHARMA, INC.

/S/ William A. Carter

Date: August 20, 2003

William A. Carter, M.D.
Chief Executive Officer & President

/S/ Robert E. Peterson

Date: August 20, 2003

Robert E. Peterson
Chief Financial Officer